Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
While applications for 1-Phase PFC are now familiar and prevalent, the same is not the case with 3-Phase PFC. Many equipments using kilowatts of power from 3-Phase mains should be candidates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback